Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory and Relapsed T Cell Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT04541017
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

Who this might be right for
Mycosis FungoidesRecurrent Mycosis FungoidesRecurrent Mycosis Fungoides and Sezary Syndrome+9 more
National Cancer Institute (NCI) 8
Early research (Phase 1)UnknownNCT05387226
What this trial is testing

Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma

Who this might be right for
T-cell LymphomaVirusIntravenous Injection
The First Affiliated Hospital of Bengbu Medical University 6
Testing effectiveness (Phase 2)Ended earlyNCT03287817
What this trial is testing

Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma

Who this might be right for
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Autolus Limited 52
Early research (Phase 1)UnknownNCT04118868
What this trial is testing

Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.

Who this might be right for
Mycosis Fungoides
Sorrento Therapeutics, Inc. 10
Testing effectiveness (Phase 2)Study completedNCT04703686
What this trial is testing

Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

Who this might be right for
Diffuse Large B-Cell Lymphoma RefractoryRefractory Indolent Adult Non-Hodgkin LymphomaRefractory Transformed B-cell Non-Hodgkin Lymphoma+2 more
The Lymphoma Academic Research Organisation 67
Testing effectiveness (Phase 2)Looking for participantsNCT07062627
What this trial is testing

Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma

Who this might be right for
Primary CNS Lymphoma (PCNSL)Diffuse Large B Cell Lymphoma (DLBCL)
Hyungwoo Cho 12
Testing effectiveness (Phase 2)Study completedNCT00787761
What this trial is testing

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

Who this might be right for
Myeloproliferative DisordersKidney CancerLeukemia+4 more
Northside Hospital, Inc. 24
Early research (Phase 1)WithdrawnNCT01236586
What this trial is testing

RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia

Who this might be right for
LymphomaBrain NeoplasmsSarcoma+2 more
National Cancer Institute (NCI)
Very early researchActive Not RecruitingNCT05651178
What this trial is testing

Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients

Who this might be right for
Central Nervous System Lymphoma
Hrain Biotechnology Co., Ltd. 10
Testing effectiveness (Phase 2)Ended earlyNCT02999633
What this trial is testing

Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia

Who this might be right for
T-cell Type Acute Leukemia-PrecursorT-lymphoblastic Lymphoma/Leukaemia
Sanofi 14
Early research (Phase 1)Looking for participantsNCT07465835
What this trial is testing

ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

Who this might be right for
T Cell Malignancies
Electra Therapeutics Inc. 84
Not applicableUnknownNCT04785833
What this trial is testing

CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia

Who this might be right for
T-ALL
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 20
Early research (Phase 1)UnknownNCT04007978
What this trial is testing

Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies

Who this might be right for
B Cell LymphomaAcute Lymphoblastic Leukemia
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 50
Early research (Phase 1)Study completedNCT02783625
What this trial is testing

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

Who this might be right for
LymphomaRelapsed/Refractory T-cell Lymphomas
Memorial Sloan Kettering Cancer Center 114
Early research (Phase 1)Study completedNCT00070538
What this trial is testing

VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies

Who this might be right for
LeukemiaMyelodysplastic Syndromes
Vion Pharmaceuticals
Early research (Phase 1)UnknownNCT05900089
What this trial is testing

Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma

Who this might be right for
Peripheral T Cell Lymphoma
Henan Cancer Hospital 30
Testing effectiveness (Phase 2)Study completedNCT00959686
What this trial is testing

Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma

Who this might be right for
T-cell Lymphoma
French Innovative Leukemia Organisation 45
Testing effectiveness (Phase 2)Ended earlyNCT03743246
What this trial is testing

Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

Who this might be right for
Precursor Cell Lymphoblastic Leukemia-LymphomaLymphoma, Non-Hodgkin
Celgene 21
Early research (Phase 1)WithdrawnNCT05519527
What this trial is testing

STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis

Who this might be right for
Refractory T Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT07009002
What this trial is testing

BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma

Who this might be right for
B Cell Lymphoma
Chinese PLA General Hospital 30
Next Page